While precision oncology continues to refine therapies targeting genetic aberrations (e.g., KRAS inhibitors and bispecific T‐cell engagers), a paradigm shift is emerging: molecular patho‐epidemiology now bridges tumor biology with population‐level data, uncovering how gene–environment–lifestyle interactions drive heterogeneity in cancer outcomes [30]. This evidence concerns the gene KRAS and neoplasm.